Cargando…
Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study
Serum myostatin and indoxyl sulfate (IS) levels increase with kidney function decline and may function as uremic toxins in chronic kidney disease (CKD)-related sarcopenia. Herein, we analyzed the association between serum myostatin and IS levels and sarcopenia in patients with CKD, by performing a p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610577/ https://www.ncbi.nlm.nih.gov/pubmed/36287929 http://dx.doi.org/10.3390/toxins14100660 |
_version_ | 1784819305742860288 |
---|---|
author | Lee, Su Mi Han, Mi Yeun Kim, Su Hyun Cha, Ran Hui Kang, Seock Hui Kim, Jun Chul An, Won Suk |
author_facet | Lee, Su Mi Han, Mi Yeun Kim, Su Hyun Cha, Ran Hui Kang, Seock Hui Kim, Jun Chul An, Won Suk |
author_sort | Lee, Su Mi |
collection | PubMed |
description | Serum myostatin and indoxyl sulfate (IS) levels increase with kidney function decline and may function as uremic toxins in chronic kidney disease (CKD)-related sarcopenia. Herein, we analyzed the association between serum myostatin and IS levels and sarcopenia in patients with CKD, by performing a post hoc analysis of baseline data extracted from the RECOVERY study (clinicaltrials.gov: NCT03788252) of 150 patients with CKD. We stratified patients into two groups according to the median value of myostatin (cutoff 4.5 ng/mL) and IS levels (cutoff 0.365 mg/dL). The proportion of patients with sarcopenia was higher in those with high IS levels but lower in those with high myostatin levels. The skeletal muscle mass index (SMI) and handgrip strength (HGS) were significantly lower in patients with high IS levels but significantly higher in patients with high myostatin levels. IS levels showed a negative correlation with glomerular filtration rate (GFR), SMI, and HGS. However, myostatin levels were positively correlated with SMI and HGS, but not with GFR. Sarcopenia was independently associated with age and IS level after adjustment. Increased levels of serum total IS might play a role in sarcopenia, while increased levels of serum myostatin are associated with muscle mass in patients with CKD. |
format | Online Article Text |
id | pubmed-9610577 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96105772022-10-28 Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study Lee, Su Mi Han, Mi Yeun Kim, Su Hyun Cha, Ran Hui Kang, Seock Hui Kim, Jun Chul An, Won Suk Toxins (Basel) Article Serum myostatin and indoxyl sulfate (IS) levels increase with kidney function decline and may function as uremic toxins in chronic kidney disease (CKD)-related sarcopenia. Herein, we analyzed the association between serum myostatin and IS levels and sarcopenia in patients with CKD, by performing a post hoc analysis of baseline data extracted from the RECOVERY study (clinicaltrials.gov: NCT03788252) of 150 patients with CKD. We stratified patients into two groups according to the median value of myostatin (cutoff 4.5 ng/mL) and IS levels (cutoff 0.365 mg/dL). The proportion of patients with sarcopenia was higher in those with high IS levels but lower in those with high myostatin levels. The skeletal muscle mass index (SMI) and handgrip strength (HGS) were significantly lower in patients with high IS levels but significantly higher in patients with high myostatin levels. IS levels showed a negative correlation with glomerular filtration rate (GFR), SMI, and HGS. However, myostatin levels were positively correlated with SMI and HGS, but not with GFR. Sarcopenia was independently associated with age and IS level after adjustment. Increased levels of serum total IS might play a role in sarcopenia, while increased levels of serum myostatin are associated with muscle mass in patients with CKD. MDPI 2022-09-23 /pmc/articles/PMC9610577/ /pubmed/36287929 http://dx.doi.org/10.3390/toxins14100660 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Su Mi Han, Mi Yeun Kim, Su Hyun Cha, Ran Hui Kang, Seock Hui Kim, Jun Chul An, Won Suk Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study |
title | Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study |
title_full | Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study |
title_fullStr | Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study |
title_full_unstemmed | Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study |
title_short | Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study |
title_sort | indoxyl sulfate might play a role in sarcopenia, while myostatin is an indicator of muscle mass in patients with chronic kidney disease: analysis from the recovery study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610577/ https://www.ncbi.nlm.nih.gov/pubmed/36287929 http://dx.doi.org/10.3390/toxins14100660 |
work_keys_str_mv | AT leesumi indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy AT hanmiyeun indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy AT kimsuhyun indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy AT charanhui indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy AT kangseockhui indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy AT kimjunchul indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy AT anwonsuk indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy |